Statins in Combinations: From ARBITER-6 HALTS to ACCORD—What Works?
- Michael Clearfield
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Taylor AJ, Villines TC, Stanek EJ, et al.: extended-release niacin or ezetimibe and carotid intima-thickness. N Engl J Med 2009, 361:2113–2122.
Statin therapy in both primary and secondary prevention studies has been shown to be effective in significantly reducing cardiovascular events . Reductions in low-density lipoprotein cholesterol (LDL-C) clearly lead to reductions in cardiovascular events, yet a significant number of events still remain in those treated. Although statins are the cornerstone for lipid medication interventions, other lipid-modifying medications such as niacin  and cholestyramine , as well as non-medication interventions such as lifestyle changes  and intestinal bypass , have also resulted in positive clinical outcomes. For most of these trials, the therapeutic target has been a reduction of LDL-C; however, even with more aggressive approaches cardiovascular events continue to occur. This residual risk may be related t
- Cholesterol Treatment Trialists Collaboration. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 2005;366:1267–1278. CrossRef
- Canner PL, Berge KG, Wenger NK et al.: Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255. CrossRef
- The Lipid Research Clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. (LRC-CPPT) JAMA 1984;251:351–364.
- Ornish D, Brown SE, Scherwitz LW et al.: Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129–133. CrossRef
- Buchwald H, Varco RL, Matts JP et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report on the Program on the Surgical Control of Hyperlipidemia (POSCH) N Engl J Med 1990;323:946–955. CrossRef
- Ridker PM, Danielson E, Fonseca F et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2197–2207. CrossRef
- Cannon CP, Braunwald E, MCabe et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495–1504. CrossRef
- Brown BG, Albers JJ, Fisher LF et al.: Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289–1298. CrossRef
- Kastelein JJ, Akdim F, Stroes E et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431–1443. CrossRef
- Fleg JL, Mete M, Howard BV et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes. The SANDS Trial. J Am Coll Cardiol 2008;52:2198–2205. CrossRef
- Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins or the combination for the prevention or coronary artery disease. N Engl J Med 2001;345:1583–1592. CrossRef
- Bassler D, Briel M, Montori Vm et al.: STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180–1187. CrossRef
- Taylor AJ, Sullenberger LE, Lee HJ et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER 2). Circulation 2004;110:3512–3517. CrossRef
- Wilson PW, Anderson KM, Castelli WP. Twelve year incidence coronary heart disease in middle aged adults during the era of hypertensive therapy. Framingham Offspring Study. Am J Med 1991;90:11–16. CrossRef
- Gordon DJ, Rifkind BM. High density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989;321:1311–1316. CrossRef
- Mosca L, Appel LJ, Benjamin EJ et al.: Evidence based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672–693. CrossRef
- Clearfield M. Clinical Trial Reports: Torcetrapib and the progression of coronary atherosclerosis. Curr Atheroscler Reports 2008;10:7–10.
- Grundy SM, Cleeman JI, Mertz CN et al.: National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239. CrossRef
- Brown BG, Stukovsky KH, Zhao XQ. Simultaneous LDL-C lowering and HDL-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized trials. Curr Opin Lipidol 2006;17:631–636. CrossRef
- Duivenvoorden DS, Gorbbee DE, Kastelein JJ et al.: Ultrasound protocols to measure carotid intima –media thickness in trials; comparison of reproducibility, rate of progression and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010;
- Blumenthal RS, Michos ED. The HALTS Trial-Halting atherosclerosis or halted too early? N Engl J Med 2009;
- Zhao XQ, Krasuski RA, Baer J et al.: Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: A combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS) and the Armed Forces Regression Study (AFREGS). Am J Cardiol 2009;104:1457–1464 CrossRef
- Nissen SE, Nicholls SJ, Sipahi et al.: Effect of very high intensity statin therapy on regression of coronary atherosclerosis. JAMA 2006;295:1556–1565. CrossRef
- Nicholls SJ, Tuzcu EM, Sipahi I et al.: Statins, HDL-C and regression of coronary atherosclerosis. JAMA 2007;297:499–508. CrossRef
- Califf RM, Lokhnugina Y, Cannon CP et al.: An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J 2010;159:705–709. CrossRef
- Statins in Combinations: From ARBITER-6 HALTS to ACCORD—What Works?
Current Atherosclerosis Reports
Volume 13, Issue 1 , pp 4-8
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Author Affiliations
- 1. Touro University College of Osteopathic Medicine, 1310 Johnson Lane, Mare Island, Vallejo, CA, 94592, USA